Actualités

Bristol Myers Squibb (BMY) reached $60.48 at the closing of the latest trading day, reflecting a +2.99% change compared to its last close.

The pharma division is firing on all cylinders, but a sudden crack in the MedTech business has the market worried about the company's new two-part growth plan.

FDA has accepted Bristol Myers Squibb's New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. The filing is supported by a Phase 3 trial that showed a meaningful improvement in progression free survival for this patient group. This decision marks a key regulatory milestone for NYSE:BMY's oncology pipeline and could influence how investors view its future revenue mix. Bristol-Myers Squibb enters this news cycle...

Bristol Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

(Bloomberg) -- AdvanCell Pty, a biotechnology firm backed by Eli Lilly & Co., has raised $315 million in new funding, underscoring investor confidence in its experimental cancer therapy.Most Read from BloombergThailand Scraps Plan to End Visa-Free Entry for Indian TouristsTrump Drops 20% Fee for Hormuz Cargo After Gulf PressureUS Hits Iran With Strikes, Blockade as Trump Plans Hormuz ChargeOpenAI’s First Device Will Be Movable, Screenless Speaker Built as AI Companion‘We Faltered’: IBM Plunges M

BMY's FDA filing for mezigdomide in relapsed or refractory multiple myeloma marks another step in advancing its protein degrader pipeline.

Drug pricing matters, but pipelines matter even more.

For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.

The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Agenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.

CYTK enters a new era after Myqorzos FDA approval, with early US uptake, European expansion and lifecycle studies fueling its commercial momentum.

Pfizer's (PFE) second-quarter revenue is expected to match Wall Street's estimates, while its earnin

Bristol-Myers Squibb (BMY) was recently removed from several Russell growth benchmarks and added to the Russell 1000 Defensive and Russell 1000 Value-Defensive indices, shifting how many institutional investors may gain exposure to the stock. See our latest analysis for Bristol-Myers Squibb. At a share price of US$57.54, Bristol-Myers Squibb has seen mixed short term moves, with the 7 day share price return of 1.95% and 30 day share price return of 3.55% contrasting with a 90 day decline of...

Prothena shares climb as late-stage partnered programs advance, milestone payments strengthen finances and its neurodegenerative pipeline continues to expand.

Get paid a guaranteed income now on your Amgen shares, which you keep no matter what, in exchange for agreeing to sell at a price that's already a win.

Bristol Myers Squibb (NYSE:BMY) Foundation’s QUILS initiative is reshaping lung cancer early detection in Kentucky. The program is now serving as a model for similar efforts in Mississippi and Nevada. QUILS targets earlier identification of lung cancer in regions with some of the highest reported rates in the country. Bristol Myers Squibb operates as a global biopharmaceutical company with a focus on oncology, immunology, and cardiovascular treatments. The QUILS initiative adds a public...

AbbVie's stock commands a king's ransom, but its performance metrics rule the kingdom, leaving investors to ask if they are buying at the top of the reign.

Bristol-Myers Squibb is expected to report its second-quarter earnings later this month, and Wall Street is calling for a double-digit decrease in profit.

In late June 2026, Janux Therapeutics, Inc. was removed from several Russell growth and small-cap benchmarks, including the Russell 2000 Growth, 2500 Growth, Small Cap Comp Growth, 3000E Growth, and 3000 Growth indexes. This broad index removal matters because it can force index-tracking funds to rebalance, potentially changing who holds the stock and how it trades. Next, we’ll examine how Janux’s removal from multiple Russell growth indexes shapes the company’s investment narrative for...

SLS009 traces back to Sellas’ 2022 GenFleet licensing deal, when the company obtained rights outside Greater China to GFH009, now known as SLS009.

In late June 2026, Bristol-Myers Squibb was removed from several Russell growth benchmarks and added to the Russell 1000 Value-Defensive and Russell 1000 Defensive indices, marking a reclassification of the stock within major index families. This shift signals that index providers now view Bristol-Myers Squibb more as a defensive, income-oriented holding than a growth-driven pharmaceutical name, aligning with its dividend profile and efforts to manage patent expirations. Next, we will...

Bristol-Myers Squibb stock has logged a solid 29.2% return over the past year, yet its valuation checks point to a mixed picture rather than a straightforward bargain or an obviously expensive share price. The 29.2% gain over the past 12 months puts recent shareholders in a strong position, raising the question of how much of the good news is already reflected in the price. Investor attention on new oncology and cardiology programs, including recent trial collaborations and regulatory...

They may not remain cheap for too much longer.

Finding stocks with generous dividends isn’t easy these days, and with packaged food giant Conagra recently getting demoted from the S&P 500, Pfizer is now the highest yielding stock in the benchmark index. The drug company, which has made quarterly payouts more than 80 straight years, is certain to get a lot of attention from dividend hunters. Pfizer’s high yield reflects investors’ trepidation over the stock.

This big pharma stock looks attractive for income investors -- but it comes with some risk.

RHHBY announces positive phase III Krascendo 1 results for divarasib in KRAS G12C NSCLC, showing PFS and OS gains versus approved inhibitors.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index and the State

Healthcare stocks were higher Thursday afternoon, with the NYSE Healthcare Index rising 2% and the S